All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
ESH 2019 | Why should we target RUNX1 in AML treatment?
Bookmark this article
The AML Global Portal were delighted to speak to Guy Sauvageau, Maisonneuve-Rosemont Hospital, Montreal, CA, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Guy Sauvageau: Why should we target RUNX1 in AML treatment?
Guy Sauvageau explains targeting RUNX1 in AML treatment. He explains different subsets of genetic mutations confer different treatment response and discusses his work in identifying small molecule compounds that aims to reinstate sensitivity to treatment in a specific subset of AML.
Why should we target RUNX1 in AML treatment?
More about...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox